Navigation Links
InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA

BRITISH COLUMBIA, Canada, Jan. 13 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces the completion of a large scale primate study confirming effectiveness and safety of its lead candidate DXL625 (CD20). The Company also announced that it has scheduled a meeting with the United States Food and Drug Administration (FDA) during the first half of 2009 to discuss the design of a clinical study.

"This study confirms that DXL625 is specific to the CD20 antigen present on NHL tumor cells and is a major milestone in our plan for clinical and commercial success," said Jeff Morhet, CEO and Chairman of InNexus. "This success paves the way for the filing of an IND and commencement of clinical trials of DXL625 in the near future." Complete results from this study are being compiled and will be presented at the annual scientific meeting of the American Association for Cancer Research (AACR) this spring.

InNexus' recently completed study was designed to confirm DXL625's in vivo safety and efficacy. The candidate was effective in completely eliminating all lymphocytes with a CD20 marker within hours at the lowest dose tested. No adverse events were seen even at a dose 100-fold higher than the lowest dose. The CD20 marker is the same as that found on tumors cells in patients with Non-Hodgkins Lymphoma patients. Previous studies have shown that DXL625 has greater potency as compared to existing therapeutic antibodies.

Pre-clinical data show that DXL625 has a safety profile equal to Rituxan(R) when evaluated in the same validated model. The preclinical study was conducted with a single injection, which confirms the remarkable potency of DXL625. In addition, the study showed no difference in immunogenicity as compared to Rituxan(R). Prior assessment of potential cross-reactivity using a limited panel of human tissue slices has revealed no off-target reactions.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds
2. Accuray Incorporated Ranked Fifth in Deloittes Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies
3. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
4. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
5. CuraGen to Present at The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
6. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
7. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
9. Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
10. Genetic Engineering and Biotechnology News reports on early ADMET use
11. China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention
Post Your Comments:
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology: